<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="186054">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671723</url>
  </required_header>
  <id_info>
    <org_study_id>12783</org_study_id>
    <nct_id>NCT00671723</nct_id>
  </id_info>
  <brief_title>Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients</brief_title>
  <official_title>Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the lack of trials proving the efficacy of DNase in non cystic fibrosis patients, it
      is currently heavily used in this population. In fact, per evidence of barcode scanning via
      Meditech computer system at OU Medical Center 93% of the DNase prescribed in 2005 was for
      non Cystic fibrosis patients with an estimated yearly cost of $341,968.15.In vitro studies
      showed that the effect of Dnase was minimal on sputum viscosity when compared to Hypertonic
      saline . Furthermore recent studies on hypertonic saline in cystic fibrosis patients showed
      that it is an inexpensive and safe therapy when preceded by a bronchodilator in patients
      with cystic fibrosis.

      We hereby propose a prospective randomized trial to compare the efficacy of hypertonic
      saline, DNase, vs. normal saline in the treatment of atelectasis in non cystic fibrosis,
      mechanically ventilated patient.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chest x-ray atelectasis score</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PO2/FIO2, Mechanical ventilation days ICU days,</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Atelectasis</condition>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dornase alpha</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline:</intervention_name>
    <description>Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic Saline</intervention_name>
    <description>Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).</description>
    <arm_group_label>Hypertonic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dornase alpha</intervention_name>
    <description>2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).</description>
    <arm_group_label>Dornase alpha</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient on invasive mechanical ventilation

          2. New Onset (&lt;48 hours) lobar or multilobar lung atelectasis based on CXR

        Exclusion Criteria:

          1. Asthma

          2. Severe COPD (FEV1&lt;30%)

          3. Pneumothorax or massive pleural effusion, thought to be causing the atelectasis

          4. Lobar atelectasis secondary to compressive tumor.

          5. Severe hypoxemia (PaO2/FiO2 &lt; 75)

          6. Hemodynamic Instability

          7. Cystic fibrosis patients

          8. Allergy to DNase

          9. Patients on Acetylcysteine

         10. Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Keddissi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Presbyterian Hospital</name>
      <address>
        <city>Oklahoma city</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>April 30, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atelectasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Atelectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
